Title: Stellate ganglion block for the management of hot flashes and sleep disturbances in breast cancer survivors : an uncontrolled experimental study with 24 weeks of follow-up
Authors: Haest, Kim
Kumar, Ariane
Van Calster, Ben
Leunen, Karin
Smeets, Ann
Amant, Frédéric
Berteloot, Patrick
Wildiers, Hans
Paridaens, Robert
Van Limbergen, Erik
Weltens, Caroline
Janssen, Hilde
Peeters, Stéphanie
Menten, Joannes
Vergote, Ignace
Morlion, Bart
Verhaeghe, Johan
Christiaens, Rose
Neven, Patrick # ×
Issue Date: Jun-2012
Publisher: Kluwer Academic Publishers
Series Title: Annals of Oncology vol:23 issue:6 pages:1449-1454
Abstract: BACKGROUND: We studied the stellate ganglion block (SGB) recently suggested for the treatment of severe vasomotor symptoms and sleep disturbances in breast cancer survivors. Following an initial pilot study, which focused on the acceptability and safety of SGB for this important problem, we evaluated its short- and long-term efficacy.Materials and methods: Postmenopausal breast cancer survivors with severe vasomotor symptoms resistant to standard nonhormonal pharmacological intervention were eligible. Diaries were used to measure daily hot flash scores (frequency and intensity) and sleep quality (Pittsburgh Sleep Quality Index) during scheduled visits at baseline, 1, 4, 12 and 24 weeks following the SGB. Efficacy data were analyzed using longitudinal regression models. RESULTS: Thirty-four patients participated and none refused the SGB procedure. Most patients received more than one SGB. The pilot study found SGB to be safe. In the main study, hot flash scores were reduced from baseline by 64% [95% confidence interval (CI) -74% to -49%] and 47% (95% CI -62% to -27%) at weeks 1 and 24, respectively. The odds ratio of better sleep quality relative to baseline was 3.4 at week 1 (95% CI 1.6-7.2) and 4.3 at week 24 (95% CI 1.9-9.8). CONCLUSION: In the short term, SGB appears to be an effective treatment with acceptable morbidity for some breast cancer survivors with therapy-resistant vasomotor symptoms and/or sleep disturbances. Although sleep quality was maintained out to 24 weeks the efficacy of SGB for hot flashes was reduced over time. A randomized controlled trial is needed to confirm these findings.
ISSN: 0923-7534
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gynaecological Oncology
Department of Health and Technology - UC Leuven
ESAT - STADIUS, Stadius Centre for Dynamical Systems, Signal Processing and Data Analytics
Organ Systems (+)
Surgical Oncology
Laboratory of Experimental Radiotherapy
Laboratory of Experimental Oncology
Faculty of Medicine - miscellaneous
Anesthesiology and Algology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science